See ASNB, HNGR, CNC, HUM, and AMN. Subscribe to Premium to view Fair Value for INVA. Recent Stock Performance Company's 52-week high was at $15.62 Company's 52-week low was at $7.58 Price action over last quarter: Up 15.67% Company Overview Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. INVA Stock Price (NASDAQ), Score, Forecast, Predictions, and Innoviva, Inc News. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Below are the latest news stories about Innoviva Inc that investors may wish to consider to help them evaluate INVA as an investment opportunity. Innoviva (NASDAQ:INVA) has had a rough month with its share price down 11%. above. As for the metrics that stood out in our discounted cash flow analysis of Innoviva Inc, consider: Want more companies with a valuation profile/forecast similar to that of Innoviva Inc? Theravance's respiratory compounds are in late-stage trial... Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter. Check if INVA has a Buy or Sell Evaluation. Innoviva Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 11.98% of tickers in our DCF set. Innoviva's stock was trading at $12.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Given that much has happened since then, and given that a stock that's trading at $11.75 is definitionally... Patrick Doyle on Seeking Alpha | … Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. BURLINGAME, Calif. Innoviva (INVA) Gains As Market Dips: What You Should Know, Innoviva Inc (INVA) Stock Quote, History and News - Yahoo Finance, Innoviva Inc (INVA) Stock Price and Basic Information | MarketWatch. The price/operating cash flow metric for Innoviva Inc is higher than just 13.34% of stocks in our set with a positive cash flow. Gross royalty revenues of $93.9 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2020 included royalties of $55.9 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $13.1 million from global net sales of ANORO® ELLIPTA® and royalties of $24.9 million from global net sales of TRELEGY® ELLIPTA®. View the latest Innoviva Inc. (INVA) stock price, news, historical charts, analyst ratings and financial information from WSJ. To summarize, we found that Innoviva Inc ranked in the 80th percentile in terms of potential gain offered. Invested an additional $12.5 million into the common stock and warrants of Entasis Therapeutics Holding Inc. (NASDAQ: ETTX), a leader in anti-infectives development. To see all exchange delays and terms of use, please see disclaimer. Gross royalty revenues of $9... Forbes - 4 months ago Top Stocks To Buy Today As … What's in Store for Innoviva (INVA) This Earnings Season? The company was founded in 1996 and is based in South San Francisco, California. This post was originally published on this site. GlaxoSmithKline plc beneficially owns 32,005,260 shares of Common Stock, which represents 31.6% of the 101,391,634 shares of Common Stock outstanding as of October 19, 2020, as reported in the Issuer’s Quarterly Report. Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. For INVA, its debt to operating expenses ratio is greater than that reported by 97.18% of US equities we're observing. In the seven months or so since I put out my cautious piece on Innoviva Inc. (INVA), the shares are down about 13% against a gain of ~24% for the S&P 500. Innoviva Inc (INVA) Stock Price | NasdaqInnoviva Inc (INVA) Stock Quote, History and News - Yahoo FinanceInnoviva Inc (INVA) Stock Price and Basic Information | MarketWatch. Stocks with similar financial metrics, market capitalization, and price volatility to Innoviva Inc are. All rights reserved. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat the estimate of $0.40. You can unlock it all now. Post-Market 0.00 (0.00%) Given that much has happened since then, and given that a stock that's trading at $11.75 is definitionally... Patrick Doyle on Seeking Alpha | … Toll-Free 877-202-1097. Given that much has happened since then, and given that a stock that's trading at $11.75 is definitionally... Patrick Doyle on Seeking Alpha | February 22, 2021, BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020. Innoviva is a biopharmaceutical company. Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter. Sign Up to See But if you pay close attention, you might... Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. BURLINGAME, Calif. Pavel Raifeld, Chief Executive Officer of Innoviva, Inc. (INVA), stated: RELVAR®/BREO® ELLIPTA® global net sales increased by 5%, ANORO® ELLIPTA® global net sales increased by 10%, and TRELEGY® ELLIPTA® global net sales increased by 42% in the fourth quarter of 2020, compared to the same quarter of 2019.Mr. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Innoviva (NASDAQ:INVA) has had a rough month with its share price down 11%. Royalties increased by 33% to $92.2 million in the third quarter of 2020, compared to the same quarter in 2019. View the real-time INVA price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Innoviva against related stocks people have also bought. Looking Ahead Innoviva hasn't issued any earnings guidance for the time being. We have 9 different ratings for every stock to help you View which stocks have been most impacted by COVID-19. Since then, INVA stock has decreased by 6.8% and is now trading at $11.22. Currency in USD, Trade prices are not sourced from all markets. Innoviva Investor Relations & Media Sloane and Company 212-486-9500. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Find market predictions, INVA financials and market news. Innoviva, Inc. NASDAQ Updated Mar 1, 2021 9:54 PM INVA 11.40 0.03 (0.26%). INVA Stock Analysis Overview What this means: InvestorsObserver gives Innoviva Inc (INVA) an overall rank of 35, which is below average. Raifeld concluded, 2020 was a strong year … Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Innoviva (NASDAQ:INVA) has had a rough month with its share price down 11%. View live INNOVIVA INC chart to track its stock's price action. By TheStreet Wire. Stock quote and company snapshot for INNOVIVA INC (INVA), including profile, stock chart, recent news and events, analyst opinions, and research reports. Is INVA A Good Stock To Buy According To Hedge Funds? © 2021 Verizon Media. • Down 9% in 2021, is Now a Good Time to Scoop Up Pfizer Stock? Benzinga does not provide investment advice. Just enter your email address below. Login Start a 14-day free trial to Morningstar Premium to unlock our take on INVA. A high-level overview of Innoviva, Inc. (INVA) stock. appreciate its future potential. • 3 Buy-Rated Value Stocks in the Technology Sector, Innoviva Reports Fourth Quarter 2020 Financial Results. In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day. See more from BenzingaClick here for options trades from BenzingaRecap: Corteva Q4 EarningsIAC/InterActiveCorp: Q4 Earnings Insights© 2021 Benzinga.com. Get the latest news and real-time alerts from Innoviva, Inc. (INVA) stock at Seeking Alpha. - Yahoo Finance finance.yahoo.com - December 19 at 7:23 AM: Is INVA A Good Stock To Buy According To Hedge Funds? The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. All rights reserved. What price target have analysts set for INVA? finance.yahoo.com - December 19 at 1:37 AM: Stock Market News for Dec 17, 2020 - Nasdaq nasdaq.com - December 18 at 3:37 PM Interest coverage, a measure of earnings relative to interest payments, is 16.54 -- which is good for besting 76.84% of its peer stocks (US stocks in the Healthcare sector with positive cash flow). • 3 Small-Cap Chinese Stocks to Buy in March. Below please find a table outlining a discounted cash flow forecast for INVA, in which we model out valuation assuming a variety of terminal growth rates. Zacks.com offers in-depth financial research with over 30years of proven results. Innoviva, Inc. is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone furoate/ vilanterol, “FF/VI”), ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”) and TRELEGY® ELLIPTA® (the combination FF/UMEC/VI). Innoviva Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. For business development inquiries, please contact investor.relations@inva.com. S&P 500 companies with more gender diversity on boards see 15% higher ROE: BofA. BURLINGAME, Calif.-- (BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020. Looking Ahead Innoviva hasn't issued any earnings guidance for the time being. Is American Electric Power Company, Inc.'s (NASDAQ:AEP) 11% ROE Better Than Average? INVA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 11.98% of tickers in our DCF set. In the seven months or so since I put out my cautious piece on Innoviva Inc. (INVA), the shares are down about 13% against a gain of ~24% for the S&P 500. View more earnings on INVA Revenue guidance hasn't been issued by the company for now. ... (INVA) Is Today's Weak On High Relative Volume Stock. Join. Find out if INVA (XNAS) is the best investment for you. In the seven months or so since I put out my cautious piece on Innoviva Inc. (INVA), the shares are down about 13% against a gain of ~24% for the S&P 500. Just click the link Find the latest news headlines from Innoviva, Inc. Common Stock (INVA) at Nasdaq.com. View more earnings on INVA Revenue guidance hasn't been issued by the company for now. Get Innoviva Inc (INVA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat the estimate of $0.40. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. Copyright © 2021. INVA: What does Argus have to say about INVA? • Why is Activision the Stock of the Week? With a price/earnings ratio of 5, Innoviva Inc P/E ratio is greater than that of about just 3.73% of stocks in our set with positive earnings. Real time Innoviva Common Stock (INVA) stock price quote, stock graph, news & analysis. INVA, Innoviva Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Innoviva Inc Stock Quote: INVA Stock News, Quotes, Analysis | Investors.com [1] In. Looking for stock market analysis and research with proves results? See Ratings...FREE! Recent Stock Performance Company's 52-week high was at $15.62 Company's 52-week low was at $7.58 Price action over last quarter: Up 15.67% Company Overview Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Revenue of $90,476,000 rose by 19.09% year over year, which beat the estimate of $74,500,000. All 'A' Rated Buy Stocks. The firm collaborates with and receives funding from GlaxoSmithKline. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Revenue of $90,476,000 rose by 19.09% year over year, which beat the estimate of $74,500,000. We expect royalties from Innoviva, Inc.’s (INVA Quick Quote INVA - Free Report) collaborated drugs to have driven revenues in fourth-quarter 2020.. …